BridgeBio Oncology Therapeutics (United States)

Homepage: bbotx.com

Alternate names: BridgeBio Oncology Therapeutics, BridgeBio Oncology Therapeutics, Inc.

ROR: 00e3m0q94

OpenAlex ID: I4405263923

Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2024 · Anna E. Maciag, James P. Stice, et al. · Cancer Discovery · 71

BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction

2025 · Dhirendra K. Simanshu, Rui Xu, et al. · Science · 40

Biophysical and structural analysis of KRAS switch-II pocket inhibitors reveals allele-specific binding constraints

2025 · Patrick Alexander, Albert H. Chan, et al. · Journal of Biological Chemistry · 26

Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR

2024 · Alok K. Sharma, Jun Pei, et al. · Journal of Biological Chemistry · 25

Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants

2026 · Carlos Stahlhut, Anna E. Maciag, et al. · Cancer Discovery · 12

Abstract P207: BBP-398, a potent, small molecule inhibitor of SHP2, enhances the response of established NSCLC xenografts to KRASG12C and mutEGFR inhibitors

2021 · James P. Stice, Sofia Donovan, et al. · Molecular Cancer Therapeutics · 12

Abstract 4378: BBO-11818, an orally bioavailable, highly potent and non-covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRAS-mutant preclinical models

2025 · Carlos Ernesto Stahlhut Espinosa, Kanchan Singh, et al. · Cancer Research · 8

Abstract RF02-02: BBO-10203, a first-in-class, orally bioavailable, selective covalent small molecule that inhibits RAS-driven PI3Kalpha activity without affecting glucose metabolism

2024 · Pedro Beltran, Simanshu Dhirendra, et al. · Cancer Research · 6

Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRAS G12C mutant non-small-cell lung cancer.

2025 · Benjamin J. Solomon, Wallace L. Akerley, et al. · Journal of Clinical Oncology · 2

Abstract 7104: BBO-11818: An orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models

2026 · Carlos E. Stahlhut Espinosa, Anna E. Maciag, et al. · Cancer Research · 1

Abstract A063: BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models

2025 · Carlos Stahlhut, Anna E. Maciag, et al. · Molecular Cancer Therapeutics · 1

Two Computer Codes (refco and Pow76) for Calculating the Fuel Cycle Cost of a Nuclear Power Reactor.

1971 · Oak Ridge National Lab., Tenn., R Salmon · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · 1

Structural mechanisms underlying resistance to Switch-II pocket inhibitors in KRAS

2026 · Matthew J. Whitley, Marcin Dyba, et al. · Nature Communications

Abstract A047: KRAS G12C and G12D mutants exhibit distinct conformational flexibility in the helix 3–switch 2 pocket that drives differential protein function

2026 · ALOK K. SHARMA, Megan Rigby, et al. · Cancer Research

Abstract B002: Structural and functional analysis of the resistance mechanisms of KRAS-G12C secondary mutations to switch-II pocket inhibitors

2026 · Matthew J. Whitley, Marcin Dyba, et al. · Cancer Research

Abstract PS5-07-06: BREAKER-101: a phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-10203 in patients with advanced solid tumors

2026 · A. Varkaris, M. Lipsyc-Sharf, et al. · Clinical Cancer Research

Abstract 3788: BBO-8520, a first-in-class direct dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, exhibits robust efficacy in non-small cell lung cancer preclinical models

2025 · James P. Stice, Anna E. Maciag, et al. · Cancer Research

Abstract A084: Use of the natural nucleotide, GTP, is essential for the identification of potent, active-state KRASG12C inhibitors that bind in the switch II pocket

2023 · Bin Wang, Alok Sharma, et al. · Molecular Cancer Therapeutics

Works count: 18

Citation count: 2,389